GH Research (NASDAQ:GHRS) Shares Gap Down to $10.50

GH Research PLC (NASDAQ:GHRS) gapped down before the market opened on Tuesday . The stock had previously closed at $10.50, but opened at $10.09. GH Research shares last traded at $9.67, with a volume of 7,987 shares changing hands.

Wall Street Analysts Forecast Growth

GHRS has been the topic of several recent research reports. JMP Securities reiterated a “market outperform” rating and issued a $39.00 price target on shares of GH Research in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research report on Thursday.

GH Research Price Performance

The business has a 50 day moving average price of $11.25 and a two-hundred day moving average price of $11.19. The stock has a market cap of $440.68 million, a P/E ratio of -13.29 and a beta of 0.86.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. On average, research analysts forecast that GH Research PLC will post -0.84 earnings per share for the current year.

Institutional Investors Weigh In On GH Research

A number of hedge funds have recently bought and sold shares of the business. AdvisorShares Investments LLC raised its position in shares of GH Research by 4.3% during the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock valued at $280,000 after buying an additional 1,977 shares in the last quarter. Lynx1 Capital Management LP increased its stake in GH Research by 80.1% during the first quarter. Lynx1 Capital Management LP now owns 3,310,563 shares of the company’s stock worth $35,291,000 after acquiring an additional 1,471,946 shares during the last quarter. BVF Inc. IL raised its position in GH Research by 12.1% during the fourth quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after purchasing an additional 1,125,000 shares during the period. Finally, RA Capital Management L.P. lifted its stake in shares of GH Research by 11.9% in the 1st quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock valued at $66,643,000 after purchasing an additional 664,381 shares during the last quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).